鼻咽癌放疗计划剂量优先与接受标准的国际指南
本指南由国际专家小组通过文献检索、多轮投票与迭代达成共识制定,旨在为鼻咽癌放疗计划中肿瘤体积与危及器官的剂量优先顺序和接受标准提供全球实用参考。最终推荐基于多数投票,具体参数同意百分比及替代观点见原文,临床决策仍需结合个体情况。
要点
- 指南强调剂量设定应遵循ALARA原则,平衡肿瘤覆盖与危及器官损伤风险。
- 推荐参数基于国际专家多轮匿名投票的多数共识,并列出替代观点。
- 最终处方决策应基于个体临床情况和患者对风险平衡的接受度。
核心结论
- 通过综合证据和国际专家经验交流,制定了鼻咽癌放疗剂量优先与接受标准的实用参考指南。
研究设计与样本
- 基于文献检索、已发表指南与方案回顾,经国际专家小组匿名投票与多轮迭代形成共识。
主要发现
- 国际专家意见经反复迭代,形成了关于剂量优先顺序和约束的指南。
- 原文展示了推荐参数及替代观点的最终同意百分比。
关键数值与推荐
- 原文未在摘要中报告具体剂量数值、约束阈值或同意百分比。
临床怎么用
- 指南可作为设置肿瘤体积和危及器官剂量优先与接受标准的实用参考。
- 最终治疗处方应基于个体临床情况和患者对风险平衡的接受度。
局限性
- 当前证据存在局限性,原文对此进行了讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The treatment of nasopharyngeal carcinoma requires high radiation doses. The balance of the risks of local recurrence owing to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. With advancements in technology, high target conformality is possible. Nonetheless, to achieve the best possible dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes and various OARs is fundamental. Radiation doses should always be guided by the As Low As Reasonably Practicable principle. There are marked variations in practice. This study aimed to develop a guideline to serve as a global practical reference. METHODS AND MATERIALS: A literature search on dose tolerances and normal-tissue complications after treatment for nasopharyngeal carcinoma was conducted. In addition, published guidelines and protocols on dose prioritization and constraints were reviewed. A text document and preliminary set of variants was circulated to a panel of international experts with publications or extensive experience in the field. An anonymized voting process was conducted to rank the proposed variants. A summary of the initial voting and different opinions expressed by members were then recirculated to the whole panel for review and reconsideration. Based on the comments of the panel, a refined second proposal was recirculated to the same panel. The current guideline was based on majority voting after repeated iteration for final agreement. RESULTS: Variation in opinion among international experts was repeatedly iterated to develop a guideline describing appropriate dose prioritization and constraints. The percentage of final agreement on the recommended parameters and alternative views is shown. The rationale for the recommendations and the limitations of current evidence are discussed. CONCLUSIONS: Through this comprehensive review of available evidence and interactive exchange of vast experience by international experts, a guideline was developed to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. The final decision on the treatment prescription should be based on the individual clinical situation and the patient's acceptance of optimal balance of risk.
引用
- Lee AW, Ng WT, Pan JJ, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2019. PMID: 31276776. doi:10.1016/j.ijrobp.2019.06.2540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。